Shanghai RAAS Blood Products Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shanghai Laishi Blood Products Co., Ltd. was established in 1988 with its registered address at 2009 Wangyuan Road, Fengxian District, Shanghai. Listed on the Shenzhen Stock Exchange in June 2008, it is a leading domestic blood product enterprise that integrates raw plasma collection, research and development, production, and sales of blood products. Shanghai Laishi is a leading blood product manufacturer in the domestic blood product industry, with a reasonable structure, complete product range, and high plasma utilization rate. The company adheres to the quality policy of "safety, quality, and efficiency", strictly follows the "Drug Management Law", "Good Manufacturing Practice for Drugs", "Chinese Pharmacopoeia", and references relevant laws and regulations in the United States and Europe to establish a comprehensive quality management system. The main products include: human serum albumin, intravenous human immunoglobulin (PH4), human coagulation factor VIII, human fibrinogen, human prothrombin complex, human thrombin Human fibrin adhesive is one of the few blood product production enterprises in China that can extract six components from plasma. It is one of the most comprehensive production enterprises in the same industry in China for coagulation factor products, and also one of the few production enterprises in China that can export blood products. As of the end of April 2023, Shanghai Laishi has four blood product production bases in Shanghai, Zhengzhou, Hefei, and Wenzhou; The company and its subsidiaries and subsidiaries have 42 single plasma collection stations (including one newly approved in February 2023), distributed in 11 provinces (autonomous regions) including Guangxi, Hunan, Hainan, Shaanxi, Anhui, Guangdong, Inner Mongolia, Zhejiang, Hubei, Jiangxi, and Shandong. The number, distribution area, and annual plasma collection volume of plasma stations are among the top in the industry. Shanghai Laishi is an "advanced technology enterprise with foreign investment in Shanghai", recognized by the Shanghai Science and Technology Commission as a "high-tech enterprise", and an "academician expert workstation". Through more than 30 years of intensive cultivation and cultivation, Shanghai Laishi products have established a safe and high-quality brand image in the industry, and their quality has gained the trust of domestic consumers and recognition in the international market. Has been awarded the titles of "Shanghai Famous Trademark" and "Shanghai Famous Brand" for many consecutive years, and has been awarded the title of "Most Innovative Enterprise" by Forbes multiple times, becoming a more influential enterprise in the industry. For a long time, Shanghai Laishi products have established a safe and high-quality brand image in the industry, and the product quality has gained the trust of domestic consumers and recognition of the international market. We have always adhered to the quality policy of "safety, quality, and efficiency", fulfilled the brand promise of "Shanghai Laishi Health Guard", collected more plasma for patients, made more drugs, made better drugs, created new drugs, and benefited society. |
| Headquarter | Shanghai |
| Establish Date | 10/29/1988 |
| Listed Code | 002252.SZ |
| Listed Date | 6/23/2008 |
| Chairman | Jun Xu. |
| CEO | Jun Xu. |
| Website | www.raas-corp.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
